Latest News on FLGT

Financial News Based On Company


Advertisement
Advertisement

Possible Bearish Signals With Fulgent Genetics Insiders Disposing Stock

https://simplywall.st/stocks/us/healthcare/nasdaq-flgt/fulgent-genetics/news/possible-bearish-signals-with-fulgent-genetics-insiders-disp-1
A number of Fulgent Genetics (NASDAQ:FLGT) insiders sold shares over the last year, leading to potential concerns among investors, especially given significant selling in the past three months without any corresponding purchases. While insiders still own a substantial 39% of the company, the consistent selling activity without buying suggests a cautious outlook from within the company. This pattern of insider selling, despite a healthy level of insider ownership, prompts a deeper look into the company's prospects.

Piper Sandler maintains Fulgent Genetics at Neutral, raises price target to $25 from $19

https://www.tradingview.com/news/tradingview:9145c4305fafb:0-piper-sandler-maintains-fulgent-genetics-at-neutral-raises-price-target-to-25-from-19/
Piper Sandler has reiterated its Neutral rating on Fulgent Genetics (FLGT) while increasing its price target to $25 from $19. This new price target suggests a 4.4% downside from the stock's closing price of $26.15 on November 9th. The article briefly mentions where to find more data and analyst recommendations for Fulgent Genetics.

What Fulgent Genetics (FLGT) Said on Its Q3 Earnings Call

https://www.tradingview.com/news/marketbeat:7d0ad1c95094b:0-what-fulgent-genetics-flgt-said-on-its-q3-earnings-call/
Fulgent Genetics (FLGT) reported an 8% increase in Q3 revenue to $90.4 million, attributing the growth to Bako Diagnostics, StrataDx, and improved collections. The company reaffirmed its full-year revenue guidance and narrowed its projected loss, despite ongoing challenges with its billing transition. Additionally, Fulgent Genetics highlighted advancements in its AI platform for pathology and progress in its therapeutic programs for cancer.

Fulgent Genetics (NASDAQ:FLGT) Shares Up 20.3% After Better-Than-Expected Earnings

https://www.marketbeat.com/instant-alerts/price-fulgent-genetics-nasdaq-flgt-shares-up-203-after-better-than-expected-earnings-2026-11-06/
Fulgent Genetics (NASDAQ:FLGT) shares surged 20.3% after the company reported better-than-expected quarterly earnings. The company posted an adjusted loss of $0.09 per share, significantly beating analyst estimates of a $0.65 loss, and revenue of $90.41 million, which also exceeded expectations. Despite the strong performance, analysts maintained a consensus "Hold" rating with an average price target of $27.50.

Fulgent Reports Third Quarter 2026 Financial Results

https://www.biospace.com/press-releases/fulgent-reports-third-quarter-2026-financial-results
Fulgent Genetics, Inc. announced its financial results for the third quarter of 2026, reporting revenue of $90.4 million, an 8% year-over-year increase, and a GAAP loss of $13.2 million. The company ended the quarter with $652.4 million in cash and investments and maintained its annual revenue guidance of $330.0-$340.0 million while improving its outlook for annual non-GAAP loss and cash guidance due to disciplined spending. Fulgent also highlighted momentum in its therapeutics pipeline and the ongoing integration of AI into its laboratory services.
Advertisement

Fulgent Genetics Inc (FLGT) Q3 2026 Earnings Call Highlights: Revenue Climbs 8% as Anatomic ...

https://sg.finance.yahoo.com/news/fulgent-genetics-inc-flgt-q3-052634471.html
Fulgent Genetics Inc (FLGT) reported Q3 2026 revenue of $90.4 million, an 8% year-over-year increase, driven by strong growth in Anatomic Pathology and Biopharma Services, despite a decline in Precision Diagnostics. The company improved its non-GAAP gross and operating margins and raised its full-year 2026 non-GAAP EPS guidance. Fulgent also advanced its therapeutic development pipeline and continues to integrate AI into its diagnostic processes.

Fulgent Genetics Latest Results: FY26 adj EPS guidance raised to $(1.75)

https://scanx.trade/stock-market-news/companies/fulgent-genetics-latest-results-fy26-adj-eps-guidance-raised-1-75/55460033
Fulgent Genetics reported an 8% increase in Q3 revenue to $90.4 million, driven by the integration of Vocal Diagnostics and STRADA Dx. The company raised its FY26 adjusted EPS guidance to a range of $(1.75) to $(1.65), surpassing analyst estimates, reflecting improved operational efficiency and disciplined spending. Fulgent also strengthened its cash position to $652.4 million, aided by a $112.3 million federal tax refund, while maintaining its FY26 sales guidance of $330 million to $340 million.

Fulgent Genetics, Inc. (FLGT) Tops Q3 EPS by 56c ; Offers Guidance

https://www.streetinsider.com/Earnings/Fulgent+Genetics%2C+Inc.+%28FLGT%29+Tops+Q3+EPS+by+56c+%3B+Offers+Guidance/27300016.html
Fulgent Genetics, Inc. (FLGT) reported Q3 EPS of ($0.09), significantly beating the analyst estimate of ($0.65) by $0.56, with revenue also exceeding expectations at $90.4 million against a consensus of $86.3 million. The company provided its FY2026 guidance, projecting EPS between ($1.65)-($1.75) and revenue of $330-340 million, both largely aligning with or surpassing analyst consensus.

Price-Driven Insight from (FLGT) for Rule-Based Strategy

https://news.stocktradersdaily.com/news_release/89/Price-Driven_Insight_from_FLGT_for_Rule-Based_Strategy_110126065402_1793534042.html
This article provides a price-driven analysis for Fulgent Genetics Inc. (NASDAQ: FLGT) based on AI models, identifying a mid-channel oscillation pattern and a strong risk-reward short setup. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide investors. The report highlights divergent sentiment across horizons, suggesting choppy market conditions for FLGT.

Fulgent Genetics, Inc. (FLGT) Seasonal returns chart

https://uk.finance.yahoo.com/quote/FLGT/seasonality/
This article provides a seasonality chart for Fulgent Genetics, Inc. (FLGT), displaying the average monthly price returns from 2016 to 2026. It includes current stock data such as the real-time price, daily change, and after-hours activity. The page also features navigation options for news, finance, sport, and various market data.
Advertisement

Fulgent Genetics, Inc. (FLGT) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/FLGT/seasonality/
The article provides a seasonal returns chart for Fulgent Genetics, Inc. (FLGT) on Yahoo Finance. It shows the average monthly price return for the company from 2016 to 2026. The stock closed at $20.62, down 4.89% on October 30.

Form 4 Fulgent Genetics Inc: Hanlin Gao (Chief Scientific Officer) For: 26 October

https://ca.investing.com/news/stock-market-news/form-4-fulgent-genetics-inc-hanlin-gao-chief-scientific-officer-for-26-october-93CH-4911037
This article reports on a Form 4 filing for Fulgent Genetics Inc, specifically detailing a transaction involving Hanlin Gao, the Chief Scientific Officer, on October 26. These filings are mandatory disclosures of stock transactions by company insiders, providing transparency to investors. The piece highlights the company's stock symbol FLGT and its daily performance.

Fulgent Genetics | 4: Statement of changes in beneficial ownership of securities-Officer Kim Paul

https://www.moomoo.com/news/notice/1002703348/statement-of-changes-in-beneficial-ownership-of-securities-officer-kim
This document, a Statement of Changes in Beneficial Ownership of Securities (Form 4), reports transactions made by Kim Paul, an Officer at Fulgent Genetics. It details changes in their beneficial ownership of the company's securities.

Form 4 Fulgent Genetics Inc: Hanlin Gao (Chief Scientific Officer) For: 26 October

https://uk.investing.com/news/stock-market-news/form-4-fulgent-genetics-inc-hanlin-gao-chief-scientific-officer-for-26-october-93CH-4939199
This article reports on a Form 4 filing for Fulgent Genetics Inc, specifically detailing an insider transaction involving Hanlin Gao, the Chief Scientific Officer, on October 26. The article itself is very brief, serving primarily as an announcement of the filing. It indicates that the information was published on October 28, 2026, at 20:46.

Fulgent Genetics, Inc. Estimates – NASDAQ:FLGT

https://www.tradingview.com/symbols/NASDAQ-FLGT/financials-estimates/
This page provides financial estimates and actuals for Fulgent Genetics, Inc. (FLGT) on the Nasdaq Stock Market. Users can explore reported financial data and analyst estimates across various financial statements and valuation metrics. The platform allows comparison of actual results with average, high, and low estimates, and visualization of trends over time.
Advertisement

Fulgent Genetics (NASDAQ:FLGT) Dips Below Its Short-Term Average

https://kalkinemedia.com/us/stocks/healthcare/fulgent-genetics-nasdaqflgt-dips-below-its-short-term-average
Fulgent Genetics (NASDAQ:FLGT) shares dipped below their short-term moving average after reporting a quarter that missed both earnings and revenue expectations. The genetic testing firm is working to rebuild growth after the pandemic testing boom, with full-year guidance still pointing to negative results. Despite the challenges, rating firms are gradually easing their pessimism, and the company continues to focus on its next-generation sequencing platform for inherited and acquired disease testing.

Fulgent Genetics Inc. R (7F0.MU) Q2 FY2026 earnings call transcript

https://finance.yahoo.com/quote/7F0.MU/earnings/7F0.MU-Q2-2026-earnings_call-659125.html/
Fulgent Genetics reported Q2 2026 revenue of $85.4 million, a 4% increase year-over-year, largely due to the integration of Bako and StrataDx. The company faced challenges with its billing and revenue cycle management system transition, leading to a decline in gross margin to 30.1% GAAP and a downward revision of full-year revenue guidance to $330M–$340M. Despite these operational hurdles, Fulgent is progressing with its therapeutic pipeline, aiming for a Phase III trial for FID-007 in early 2027, and expanding its AI and digital pathology solutions.

Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026

https://www.streetinsider.com/Business+Wire/Fulgent+to+Announce+Third+Quarter+2026+Financial+Results+on+Thursday%2C+November+5%2C+2026/27193348.html
Fulgent Genetics, Inc. (NASDAQ: FLGT) announced it will release its third quarter 2026 financial results after the market closes on Thursday, November 5, 2026. Following the release, management will host a conference call at 4:30 PM ET to discuss the results and answer investor questions. The call will be accessible via live audio webcast on the company's Investor Relations website.

Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026

https://finance.yahoo.com/healthcare/articles/fulgent-announce-third-quarter-2026-200500755.html
Fulgent Genetics, Inc. (NASDAQ: FLGT) will release its third quarter 2026 financial results after the market closes on Thursday, November 5, 2026. Management will host a conference call on the same day at 4:30 PM ET to discuss the results and answer questions, which can be accessed via live audio webcast on the Company's investor relations website. Fulgent is a technology-based company with established laboratory services and a therapeutic development business focused on cancer drug development.

Fulgent to Announce Third Quarter 2026 Financial Results on Thursday, November 5, 2026

https://www.biospace.com/press-releases/fulgent-to-announce-third-quarter-2026-financial-results-on-thursday-november-5-2026
Fulgent Genetics, Inc. (NASDAQ: FLGT) announced it will release its third-quarter 2026 financial results after market close on Thursday, November 5, 2026. The company will also host a conference call and webcast on the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions. Fulgent is a technology-based company with established laboratory services and a therapeutic development business focused on cancer drug candidates.
Advertisement

Liquidity Mapping Around (FLGT) Price Events

https://news.stocktradersdaily.com/news_release/132/Liquidity_Mapping_Around_FLGT_Price_Events_101126092801_1791768481.html
This article provides a liquidity mapping analysis for Fulgent Genetics Inc. (FLGT), highlighting weak sentiment and potential for a breakout. It presents three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strengths and key support/resistance levels.

Fulgent Genetics (NASDAQ:FLGT) Shares Down 6.5% - Time to Sell?

https://www.marketbeat.com/instant-alerts/price-fulgent-genetics-nasdaq-flgt-shares-down-65-time-to-sell-2026-10-06/
Fulgent Genetics (NASDAQ:FLGT) shares dropped 6.5% to approximately $20.99 with light trading volume, bringing its market capitalization to about $570 million. The company faces a "Hold" consensus rating and missed recent quarterly earnings and revenue estimates, remaining unprofitable with negative margins. Insiders have sold shares to cover tax obligations from equity awards, and analysts forecast a full-year loss.

175,581 Shares of Fulgent Genetics, Inc. $FLGT Bought by Bank of America Corp DE

https://www.marketbeat.com/instant-alerts/filing-175581-shares-of-fulgent-genetics-inc-flgt-bought-by-bank-of-america-corp-de-2026-09-30/
Bank of America Corp DE recently acquired 175,581 shares of Fulgent Genetics (NASDAQ:FLGT) valued at approximately $3.6 million, representing 0.64% of the company's stock. Despite this institutional investment, Fulgent Genetics reported weaker-than-expected quarterly results and currently holds a consensus "Hold" rating from Wall Street analysts with an average price target of $27.50. Corporate insiders have also been selling shares, further influencing the stock's performance.

Fulgent Genetics (FLGT) Short Interest & Short Float | Updated Sep 2026

https://www.marketbeat.com/stocks/NASDAQ/FLGT/short-interest/
This article provides an updated overview of Fulgent Genetics (FLGT) short interest and short float as of September 15, 2026. The company had 2.32 million shares sold short, representing 13.20% of its public float, marking a 2.12% decrease from the previous report. The short interest ratio stands at 6.7 days to cover, indicating moderate short seller sentiment.

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

https://finance.yahoo.com/healthcare/articles/prpo-vs-flgt-cancer-diagnostics-171600072.html
This article compares two cancer diagnostics companies, Precipio, Inc. (PRPO) and Fulgent Genetics, Inc. (FLGT), to determine which offers more upside potential for investors. While PRPO focuses on hematologic cancers and is expanding its product sales, FLGT provides a broader range of genetic testing services, integrated acquisitions, AI capabilities, and a therapeutic development business. The analysis concludes that FLGT appears to have more upside due to its diversified platform, strategic acquisitions, and more reasonable valuation compared to PRPO.
Advertisement

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

https://www.tradingview.com/news/zacks:0f70fc472094b:0-prpo-vs-flgt-which-cancer-diagnostics-stock-has-more-upside-now/
This article compares two cancer diagnostics companies, Precipio, Inc. (PRPO) and Fulgent Genetics, Inc. (FLGT), to determine which stock offers more upside. While PRPO has strong growth drivers and improving cash generation, FLGT is recommended due to its more diversified platform, acquisition-driven expansion, AI capabilities, therapeutic pipeline, and a more favorable valuation compared to its historical levels.

Fulgent Genetics, Inc. $FLGT Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

https://www.marketbeat.com/instant-alerts/filing-fulgent-genetics-inc-flgt-shares-sold-by-ubs-am-a-distinct-business-unit-of-ubs-asset-management-americas-llc-2026-09-14/
UBS Asset Management significantly reduced its stake in Fulgent Genetics (NASDAQ:FLGT) by 55.6% in the second quarter, selling 56,283 shares and retaining 45,020 shares valued at approximately $924,000. Institutional investors now own 48.06% of the company. Additionally, Fulgent Genetics insiders, including Hanlin Gao and Jian Xie, sold 5,932 shares worth $117,156, primarily to cover tax obligations from vested equity awards. The company also reported missing consensus estimates for quarterly EPS and revenue, and analysts currently maintain a "Hold" rating with an average price target of $27.50.

Public Employees Retirement System of Ohio Makes New Investment in Fulgent Genetics, Inc. $FLGT

https://www.marketbeat.com/instant-alerts/filing-public-employees-retirement-system-of-ohio-makes-new-investment-in-fulgent-genetics-inc-flgt-2026-09-09/
The Public Employees Retirement System of Ohio has acquired a new stake of 55,247 shares in Fulgent Genetics, Inc. valued at approximately $1.13 million. This investment comes as institutional ownership in the company reaches 48.06%, despite Fulgent Genetics reporting weaker-than-expected quarterly results and maintaining negative profitability. Analyst sentiment is mixed, with a "Hold" rating, and two insiders recently sold shares to cover tax obligations.

Fulgent Genetics (NASDAQ: FLGT) officer to sell 45,304 vested shares for taxes

https://www.stocktitan.net/sec-filings/FLGT/144-fulgent-genetics-inc-sec-filing-93f2bdd6a95a.html
An officer at Fulgent Genetics (FLGT), Jian Xie, has filed a Rule 144 notice to sell 45,304 vested restricted shares. These shares, which vested on February 25, 2025, are being sold primarily to cover tax withholding obligations through "sell to cover" arrangements, rather than being a discretionary trade. The filing also reports two previous sales by Xie in June and August 2026 for similar tax purposes.

Fulgent Genetics president and COO Xie Jian sells $41,809 in stock By Investing.com

https://za.investing.com/news/stock-market-news/fulgent-genetics-president-and-coo-xie-jian-sells-41809-in-stock-93CH-4453995
Fulgent Genetics President and COO Xie Jian sold 2,127 shares of the company's common stock for a total of $41,809 to cover tax withholding obligations from vested restricted stock units. Following this transaction, Mr. Jian still directly owns 359,924 shares, with additional shares held indirectly. The sale comes as FLGT stock has gained 40% in six months but is down 25% year-to-date and is considered undervalued by InvestingPro.
Advertisement

Fulgent Genetics CSO Hanlin Gao sells $32,885 in stock By Investing.com

https://za.investing.com/news/stock-market-news/fulgent-genetics-cso-hanlin-gao-sells-32885-in-stock-93CH-4453993
Hanlin Gao, Chief Scientific Officer at Fulgent Genetics (NASDAQ:FLGT), sold 1,673 shares of the company's common stock for $32,885 on September 2, 2026. This sale was primarily to cover tax obligations from vested restricted stock units. Despite this, Gao still beneficially owns 986,117 shares, and InvestingPro analysis suggests Fulgent Genetics is currently undervalued with more cash than debt.

Fulgent Genetics (NASDAQ:FLGT) COO Sells 2,127 Shares

https://www.marketbeat.com/instant-alerts/insider-fulgent-genetics-nasdaq-flgt-coo-sells-2127-shares-2026-09-03/
Fulgent Genetics' COO, Jian Xie, sold 2,127 shares of the company's stock for approximately $41,816.82, primarily to cover tax obligations on vested equity awards. This sale decreased his holdings to 359,924 shares. The company's stock experienced a 1.9% dip, and its latest quarterly results missed analyst expectations with an adjusted EPS loss of $0.58 and revenue of $85.39 million.

Fulgent Genetics (NASDAQ:FLGT) Insider Sells $32,891.18 in Stock

https://www.marketbeat.com/instant-alerts/insider-fulgent-genetics-nasdaq-flgt-insider-sells-3289118-in-stock-2026-09-03/
Hanlin Gao, an insider at Fulgent Genetics (NASDAQ:FLGT), sold 1,673 shares worth $32,891.18 to cover tax withholdings on vested equity awards, reducing his stake by 0.17%. This sale follows another recent transaction of 939 shares. The company recently reported a quarterly loss of $0.58 per share, missing consensus estimates, and revenue of $85.39 million, also below expectations, leading to a consensus "Hold" rating from analysts with an average price target of $27.50.

Fulgent Genetics CSO Hanlin Gao sells $32,885 in stock

https://m.investing.com/news/insider-trading-news/fulgent-genetics-cso-hanlin-gao-sells-32885-in-stock-93CH-4888733?ampMode=1
Hanlin Gao, CSO of Fulgent Genetics (NASDAQ:FLGT), sold 1,673 shares of company stock for $32,885 on September 2, 2026, to cover tax withholding obligations from vested restricted stock units. Following this transaction, Mr. Gao beneficially owns 986,117 shares. This sale comes as the stock has gained 40% in six months, despite the company reporting an adjusted Q2 loss and revenue below expectations, leading to a lowered full-year outlook.

Fulgent Genetics president and COO Xie Jian sells $41,809 in stock

https://m.investing.com/news/insider-trading-news/fulgent-genetics-president-and-coo-xie-jian-sells-41809-in-stock-93CH-4888732?ampMode=1
Xie Jian, President and COO of Fulgent Genetics (NASDAQ:FLGT), sold 2,127 shares of company stock for $41,809 to cover tax withholding obligations from vested restricted stock units. Following the sale, Jian directly owns 359,924 shares and indirectly holds 220,816 shares through a family trust. This transaction comes after the company reported second-quarter financial results that missed Wall Street expectations, citing billing system issues and a reduced full-year outlook.
Advertisement

Fulgent Genetics (FLGT) officer plans stock sale to cover taxes

https://www.stocktitan.net/sec-filings/FLGT/144-fulgent-genetics-inc-sec-filing-16ca122e1e23.html
Fulgent Genetics officer Hanlin Gao has filed a Rule 144 notice to sell 1,673 shares of common stock on September 2, 2026, to cover tax withholding obligations related to previously vested restricted stock. This planned sale, valued at $32,885.20, is part of "sell-to-cover" transactions and not discretionary trading. Gao also reported similar tax-related sales of 1,688 shares on June 2, 2026, and 939 shares on August 27, 2026.

Fulgent Genetics president and COO Xie Jian sells $41,809 in stock

https://www.investing.com/news/insider-trading-news/fulgent-genetics-president-and-coo-xie-jian-sells-41809-in-stock-93CH-4888732
Xie Jian, President and COO of Fulgent Genetics (NASDAQ:FLGT), sold 2,127 shares worth $41,809 to cover tax obligations from vested restricted stock units. Following the sale, Mr. Jian still directly owns 359,924 shares, with additional shares held indirectly by a family trust. The company recently reported Q2 financial results that missed Wall Street's expectations due to billing system issues and a reduced full-year outlook.

Jian Xie Sells 1,193 Shares of Fulgent Genetics (NASDAQ:FLGT) Stock

https://www.marketbeat.com/instant-alerts/insider-jian-xie-sells-1193-shares-of-fulgent-genetics-nasdaq-flgt-stock-2026-08-28/
Jian Xie, COO of Fulgent Genetics (NASDAQ:FLGT), sold 1,193 shares of the company's stock for $23,752.63 to cover tax obligations. This sale reduced his holdings to 362,051 shares. The company recently reported weaker-than-expected quarterly results and currently holds a "Hold" rating from analysts with a consensus price target of $27.50.

Fulgent Genetics (NASDAQ:FLGT) Upgraded at Wall Street Zen

https://www.marketbeat.com/instant-alerts/analyst-fulgent-genetics-nasdaq-flgt-upgraded-at-wall-street-zen-2026-08-29/
Wall Street Zen upgraded Fulgent Genetics (NASDAQ:FLGT) from a "strong sell" to a "sell" rating, although the overall analyst consensus remains "Hold" with a target price of $27.50. The company recently reported an adjusted loss of $0.58 per share and missed revenue estimates for the latest quarter. Despite this, institutional investors own 48.06% of the company, and insiders recently sold shares primarily to cover tax obligations.

Almitas Capital LLC Purchases New Holdings in Fulgent Genetics, Inc. $FLGT

https://www.marketbeat.com/instant-alerts/filing-almitas-capital-llc-purchases-new-holdings-in-fulgent-genetics-inc-flgt-2026-08-28/
Almitas Capital LLC has acquired a new position in Fulgent Genetics, Inc. (NASDAQ:FLGT), purchasing 104,797 shares valued at approximately $2.15 million. This acquisition makes Almitas Capital LLC an approximate 0.38% owner of the company, with institutional investors collectively holding 48.06% of the stock. The company recently reported weaker-than-expected quarterly results, and analysts maintain a cautious outlook with an average "Hold" rating and a target price of $27.50.
Advertisement

Medina Value Partners LLC Buys New Stake in Fulgent Genetics, Inc. $FLGT

https://www.marketbeat.com/instant-alerts/filing-medina-value-partners-llc-invests-396-billion-in-fulgent-genetics-inc-flgt-2026-08-26/
Medina Value Partners LLC has acquired a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT), purchasing 193,061 shares valued at approximately $3.96 million. This makes Fulgent Genetics the 27th biggest position in Medina Value Partners LLC's investment portfolio. Other institutional investors like Amundi, Goldman Sachs Group Inc., Legal & General Group Plc, Rhumbline Advisers, and American Century Companies Inc. also adjusted their holdings in the company.

FLGT | Fulgent Genetics, Inc. Common Financials - Revenue Breakdown

https://www.quiverquant.com/stock/FLGT/financials/revenue_breakdown/
This page provides a detailed financial overview of Fulgent Genetics, Inc. (FLGT), focusing on its revenue breakdown, alongside other financial data like insider trading, institutional holdings, lobbying activities, and patent grants. It also includes analyst ratings, stock forecasts, and a company profile, while indicating that specific revenue segment data is currently unavailable.

Renaissance Technologies LLC Decreases Stock Position in Fulgent Genetics, Inc. $FLGT

https://www.marketbeat.com/instant-alerts/filing-renaissance-technologies-llc-decreases-stock-position-in-fulgent-genetics-inc-flgt-2026-08-20/
Renaissance Technologies LLC significantly reduced its stake in Fulgent Genetics, Inc. by 78.3% in Q1 2026, selling 64,864 shares and retaining 18,000 shares valued at $286,000. This divestment follows Fulgent Genetics' weaker-than-expected quarterly results, including an adjusted loss of $0.58 per share and revenue below analyst estimates. Analyst sentiment remains cautious, with an average "Hold" rating and recent downgrades.

Fulgent Genetics (NASDAQ:FLGT) Share Price Crosses Below Fifty Day Moving Average - Here's What Happened

https://www.marketbeat.com/instant-alerts/fulgent-genetics-nasdaqflgt-share-price-crosses-below-fifty-day-moving-average-heres-what-happened-2026-08-20/
Fulgent Genetics (NASDAQ:FLGT) saw its share price drop below its 50-day moving average, trading as low as $18.96 before closing at $19.74. The company missed its quarterly earnings expectations, reporting an adjusted loss of $0.58 per share against an estimated loss of $0.46, and revenue of $85.39 million compared to a $94 million consensus. Analyst sentiment remains mixed with a consensus "Hold" rating and a price target of $27.50.

Fulgent Genetics, Inc. $FLGT Shares Purchased by Quantinno Capital Management LP

https://www.marketbeat.com/instant-alerts/filing-fulgent-genetics-inc-flgt-shares-purchased-by-quantinno-capital-management-lp-2026-08-11/
Quantinno Capital Management LP significantly increased its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 374.7% in the first quarter, bringing its total holdings to 137,479 shares valued at $2.19 million. Institutional investors now own 48.06% of FLGT, while company insiders hold 36.18%, with recent insider sales primarily for tax obligations. Despite the increased institutional investment, analysts maintain a consensus "Hold" rating with a $27.50 price target, following the company's miss on quarterly revenue and EPS estimates and ongoing negative profitability.
Advertisement

Discipline and Rules-Based Execution in FLGT Response

https://news.stocktradersdaily.com/news_release/149/Discipline_and_Rules-Based_Execution_in_FLGT_Response_081026120601_1786377961.html
This article analyzes Fulgent Genetics Inc. (NASDAQ: FLGT), highlighting a near-term strong sentiment despite persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and an exceptional 98.2:1 risk-reward setup, targeting a 28.2% gain versus 0.3% risk. The article details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for various time horizons.

Fulgent Genetics, Inc. $FLGT Shares Sold by Dimensional Fund Advisors LP

https://www.marketbeat.com/instant-alerts/filing-fulgent-genetics-inc-flgt-shares-sold-by-dimensional-fund-advisors-lp-2026-08-10/
Dimensional Fund Advisors LP significantly reduced its stake in Fulgent Genetics (NASDAQ:FLGT) by 24.4% in the first quarter, selling over 217,000 shares. This comes as Fulgent Genetics reported a quarterly loss and revenue below analyst expectations, contributing to a "Hold" consensus rating among analysts. Despite some institutional investors increasing their holdings, corporate insiders also sold shares, primarily to cover tax obligations.

Fulgent Genetics (FLGT) Q2 2026 Earnings Call Transcript

https://www.theglobeandmail.com/investing/markets/stocks/FLGT/pressreleases/3731253/fulgent-genetics-flgt-q2-2026-earnings-call-transcript/
Fulgent Genetics (FLGT) reported Q2 2026 revenue of $85.4 million, up 4% year-over-year, but revised its full-year revenue guidance downward to $330-$340 million due to lower collection rates from a complex billing system transition. The company also reported an adjusted EBITDA loss of $17.1 million. Despite these challenges, Fulgent Genetics is advancing its therapeutic pipeline, with its lead oncology candidate FID-007 moving towards a Phase III trial, and is expanding its anatomic pathology services through recent acquisitions and AI integration.

Wall Street Zen Downgrades Fulgent Genetics (NASDAQ:FLGT) to Strong Sell

https://www.marketbeat.com/instant-alerts/wall-street-zen-downgrades-fulgent-genetics-nasdaqflgt-to-strong-sell-2026-08-08/
Wall Street Zen has downgraded Fulgent Genetics (NASDAQ:FLGT) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "hold" with a $27.50 price target. This downgrade follows Fulgent's recent quarterly earnings report, which missed analyst expectations for both EPS and revenue. Insiders have sold a significant number of shares, though some institutional investors have increased their holdings.

Price to sales forward of Fulgent Genetics, Inc. – MUN:7F0

https://www.tradingview.com/symbols/MUN-7F0/financials-statistics-and-ratios/price-sales-fwd/
This page from TradingView provides financial information for Fulgent Genetics, Inc. (MUN:7F0), specifically focusing on its forward price-to-sales ratio. The content appears to be a stub or a placeholder, as no specific values or detailed data regarding the price-to-sales metric are visible.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement